Summary

This article discusses the efficacy and safety results from A Randomized, Placebo-Controlled Study to Evaluate the Effect of Tocilizumab on Disease Response in Patients With Active Systemic Juvenile Idiopathic Arthritis, With an Open-Label Extension to Examine the Long-Term Use of Tocilizumab [TENDER; NCT00642460].